Macquarie Group
KROS icon

Macquarie Group’s Keros Therapeutics KROS Stock Holding History

Macquarie Group’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,372
Closed -$61K – 1950
2022
Q3 		$61K Sell
1,372
-250
-15% -$8.66K ﹤0.01% 1899
2022
Q2 		$45K Hold
1,622
– – ﹤0.01% 2077
2022
Q1 		$88K Hold
1,622
– – ﹤0.01% 1988
2021
Q4 		$95K Hold
1,622
– – ﹤0.01% 1954
2021
Q3 		$64K Buy
1,622
+1,372
+549% +$48.8K ﹤0.01% 2139
2021
Q2 		$11K Hold
250
– – ﹤0.01% 2461
2021
Q1 		$15K Buy
+250
New +$15.8K ﹤0.01% 2336

Other funds holding KROS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Macquarie Group's KROS Position: Q4 2022 in Review

Macquarie Group sold out of Keros Therapeutics (KROS) in Q4 2022, closing a stake of 1,372 shares — an estimated $61K sold.

Macquarie Group first reported a position in KROS in Q1 2021 and held it in 7 quarters. The position peaked at $95K in Q4 2021. 127 funds tracked by Wall St. Rank hold KROS as of Q4 2022.

  • Macquarie Group reported no remaining Keros Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Macquarie Group sold 1,372 Keros Therapeutics shares in Q4 2022, an estimated $61K.
  • Macquarie Group first reported a position in Keros Therapeutics in Q1 2021 and held it in 7 quarters.
  • Macquarie Group's Keros Therapeutics position peaked at $95K in Q4 2021.
  • 127 funds tracked by Wall St. Rank held Keros Therapeutics as of Q4 2022.

Based on Macquarie Group's 13F filing for Q4 2022, filed 21 Feb 2023.